Outsmarting Cancer, Impacting lives

Oncode Institute spin-off Omivera, built around the CellEKT chemical proteomics platform, has secured a seed investment from UNIIQ, an investment fund focused on the proof-of-concept phase, aiming to bring innovations to the market faster. 

The Alpe d’HuZes/KWF Fund will invest €4.5 million in Oncode Institute over the next two years. Made possible by the participants of Alpe d’HuZes, this funding accelerates innovative cancer research and enables promising ideas to more quickly develop into applications for patients. The investment supports multiple innovative research projects and aligns with the Alpe d’HuZes research themes: understanding, detection, and cure.

A novel cancer treatment strategy that enables the targeted degradation of membrane proteins has received funding from the highly competitive European Innovation Council Pathfinder programme. The OutMARCH project aims to make previously “undruggable” cancer proteins accessible, potentially offering new ways to overcome resistance to existing therapies.